Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 6, 2003, Pages 1423-1425

  Manavathu, Elias K ^a   Alangaden, George J ^a   Chandrasekar, Pranatharthi H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal combination; Aspergillus fumigatus; Caspofungin; Triazoles

Indexed keywords

ANTIFUNGAL AGENT; CASPOFUNGIN; HEXAPEPTIDE; ITRACONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CONIDIUM; CONTROLLED STUDY; DATA ANALYSIS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; FUNGUS ISOLATION; IN VITRO STUDY; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; SUSPENSION;

ASPERGILLUS FUMIGATUS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDES; PEPTIDES, CYCLIC; TRIAZOLES;

EID: 0038820107     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg242     Document Type: Article

References (10)

1. Ryder, N. S. & Leitner, I. (2001). Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Medical Mycology 39, 91-5.
2. Sanati, H., Ramos, C. F., Bayer, A. S. & Ghannoum, M. A. (1997). Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. Antimicrobial Agents and Chemotherapy 41, 1345-8.
3. Manavathu, E. K., Cutright, J. L., Loebenberg, D. & Chandrasekar, P. H. (2000). A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to: amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). Journal of Antimicrobial Chemotherapy 46, 229-34.
4. Chandrasekar, P. H., Cutright, J. & Manavathu, E. (2000). Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea pig model. Journal of Antimicrobial Chemotherapy 45, 673-6.
5. Bartizal, K., Gill, C. J., Abruzzo, G. K., Flattery, A. M., Kong, L., Scott, P. M. et al. (1997). In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrobial Agents and Chemotherapy 41, 2326-32.
6. Li, R. K. & Rinaldi, M. G. (1999). In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrobial Agents and Chemotherapy 43, 1401-5.
7. National Committee for Clinical Laboratory Standards. (2002). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-forming Filamentous Fungi: Proposed Standard M38-A. NCCLS, Wayne, PA, USA.
8. Jahn, B. E., Martin, E., Stueben, A. & Bhakdi, S. (1995). Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. Journal of Clinical Microbiology 33, 661-7.
9. Tuck, S. F., Aoyama, Y., Yoshida, Y. P. & Ortiz de Montellano, P. R. (1992). Active site topology of Saccharomyces cerevisiae lanosterol 14α-demethylase (CYP51) and its G301 mutant (cytochrome P-4503G1). Journal of Biological Chemistry 267, 13175-9.
10. 14DM purified from Saccharomyces cerevisiae microsomes. Biochemical Pharmacology 36, 229-35.